Radiation Let Two Men Stay on Their Lung Cancer Drug
Original title: Continuation of Tarlatamab With Concomitant Radiotherapy for Oligoprogression in Extensive-Stage Small-Cell Lung Cancer: A Report of Two Cases.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was tested in people. That is the most reliable kind of research we share.
Doctors only watched what happened in two men, so this plan is not proven.
The short version
Two men kept taking their cancer drug after radiation treated one growing spot.
What was studied. Doctors wrote up two men with small cell lung cancer that had spread. Both were taking a drug called tarlatamab. In each man, one spot of cancer started to grow again.
What they found. One man was 63. He had a single spot of cancer in his brain. Focused radiation shrank it a lot, and he stayed on the drug. The other man was 78. One lymph node in his chest grew. Radiation shrank it a lot, and his cancer blood test went back to normal. He also stayed on the drug.
What this means, and what it doesn't
What it could mean: Radiation to one growing spot may let some people keep taking this drug. Doctors may think about this when only one spot is growing. It is one option to ask about, not a rule.
What it doesn't mean: This is a report on two men, not a real study. Nobody compared this plan to other care. It does not prove the plan works for other people. It is not a cure. This was lung cancer that spread to the brain. It is not a tumor that started in the brain. Ask your own doctor what fits your case.
Source: PubMed, August 5, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.